New Marker in the Umbilical Cord Blood of Fetuses with Fetal Growth Restriction: Serum Sortilin-1 Level.

IF 0.7 4区医学 Q4 PATHOLOGY

Fetal and Pediatric Pathology Pub Date : 2024-10-10 DOI:10.1080/15513815.2024.2412846

Gulsan Karabay, Burak Bayraktar, Zeynep Seyhanli, Betul Tokguz Cakir, Gizem Aktemur, Serap Topkara Sucu, Nazan Vanlı Tonyali, Selma Ipek, Tugba Kolomuc Gayretli, Sevki Celen

{"title":"New Marker in the Umbilical Cord Blood of Fetuses with Fetal Growth Restriction: Serum Sortilin-1 Level.","authors":"Gulsan Karabay, Burak Bayraktar, Zeynep Seyhanli, Betul Tokguz Cakir, Gizem Aktemur, Serap Topkara Sucu, Nazan Vanlı Tonyali, Selma Ipek, Tugba Kolomuc Gayretli, Sevki Celen","doi":"10.1080/15513815.2024.2412846","DOIUrl":null,"url":null,"abstract":"Objective: To determine the role of sortilin in the pathogenesis of fetal growth restriction (FGR) by examining serum sortilin levels in fetal cord blood. Methods: This prospective case-control study was conducted at Ankara Etlik City Hospital between July 2023 and January 2024. Group 1 included 44 pregnant women with late FGR; Group 2 included 44 healthy pregnant women as controls. Results: Umbilical cord blood sortilin levels were significantly higher in the FGR group [2.96 (2.43-4.01)] compared to the control group [2.12 (1.74-3.18)] (p = 0.001). Sortilin levels negatively correlated with APGAR scores at 1 min (r=-0.281, p = 0.008) and 5 min (r=-0.292, p = 0.006). A sortilin threshold of 2.58 ng/ml predicted composite adverse neonatal outcomes with 66.7% sensitivity, 53.1% specificity, and an AUC of 0.652 (95% CI: 0.529-0.775, p = 0.031). Conclusion: This study showed that sortilin levels, which are indicators of oxidation, were higher in the cord blood of newborns with late FGR.","PeriodicalId":50452,"journal":{"name":"Fetal and Pediatric Pathology","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fetal and Pediatric Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/15513815.2024.2412846","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To determine the role of sortilin in the pathogenesis of fetal growth restriction (FGR) by examining serum sortilin levels in fetal cord blood. Methods: This prospective case-control study was conducted at Ankara Etlik City Hospital between July 2023 and January 2024. Group 1 included 44 pregnant women with late FGR; Group 2 included 44 healthy pregnant women as controls. Results: Umbilical cord blood sortilin levels were significantly higher in the FGR group [2.96 (2.43-4.01)] compared to the control group [2.12 (1.74-3.18)] (p = 0.001). Sortilin levels negatively correlated with APGAR scores at 1 min (r=-0.281, p = 0.008) and 5 min (r=-0.292, p = 0.006). A sortilin threshold of 2.58 ng/ml predicted composite adverse neonatal outcomes with 66.7% sensitivity, 53.1% specificity, and an AUC of 0.652 (95% CI: 0.529-0.775, p = 0.031). Conclusion: This study showed that sortilin levels, which are indicators of oxidation, were higher in the cord blood of newborns with late FGR.

查看原文本刊更多论文

胎儿生长受限胎儿脐带血中的新标记物：血清 Sortilin-1 水平。

目的通过检测胎儿脐带血中的血清索氏蛋白水平，确定索氏蛋白在胎儿生长受限（FGR）发病机制中的作用。方法这项前瞻性病例对照研究于 2023 年 7 月至 2024 年 1 月在安卡拉埃特里克市医院进行。第一组包括 44 名晚期 FGR 孕妇；第二组包括 44 名健康孕妇作为对照。研究结果与对照组[2.12 (1.74-3.18)]相比，FGR 组的脐带血索氏林水平[2.96 (2.43-4.01)]明显更高（p = 0.001）。Sortilin水平与1分钟（r=-0.281，p = 0.008）和5分钟（r=-0.292，p = 0.006）的APGAR评分呈负相关。2.58纳克/毫升的Sortilin阈值可预测新生儿综合不良结局，灵敏度为66.7%，特异度为53.1%，AUC为0.652（95% CI：0.529-0.775，p = 0.031）。结论本研究表明，晚期FGR新生儿脐带血中作为氧化指标的索替林水平较高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Fetal and Pediatric Pathology 医学-病理学

CiteScore

3.00

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Fetal and Pediatric Pathology is an established bimonthly international journal that publishes data on diseases of the developing embryo, newborns, children, and adolescents. The journal publishes original and review articles and reportable case reports. The expanded scope of the journal encompasses molecular basis of genetic disorders; molecular basis of diseases that lead to implantation failures; molecular basis of abnormal placentation; placentology and molecular basis of habitual abortion; intrauterine development and molecular basis of embryonic death; pathogenisis and etiologic factors involved in sudden infant death syndrome; the underlying molecular basis, and pathogenesis of diseases that lead to morbidity and mortality in newborns; prenatal, perinatal, and pediatric diseases and molecular basis of diseases of childhood including solid tumors and tumors of the hematopoietic system; and experimental and molecular pathology.